GID BIO completes enrollment for randomized double-blinded pivotal Phase III cell therapy study for treatment of knee osteoarthritis ...Middle East

LOUISVILLE, Colo., Feb. 12, 2024 /PRNewswire/ -- GID BIO, Inc. completed enrollment for the first of two pivotal Phase III studies to investigate the use of your own stromal vascular fraction (SVF) cells to treat osteoarthritis of the knee. The clinical study involves a cellular...

Hence then, the article about gid bio completes enrollment for randomized double blinded pivotal phase iii cell therapy study for treatment of knee osteoarthritis was published today ( Monday 12/02/2024 - 07:24 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( GID BIO completes enrollment for randomized double-blinded pivotal Phase III cell therapy study for treatment of knee osteoarthritis )

Also on site :

• ‘The Young and the Restless’ Legend Eileen Davidson Reveals How One ‘Topical’ Storyline Literally Saved Fans’ Lives (Exclusive)
• Think 2026: IBM Makes Digital Sovereignty Operational with General Availability of IBM Sovereign Core
• Iran war live: Washington, Tehran trade threats over Strait of Hormuz